ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / NYXH / financials
LUCD (47) MBOT (41) QTEX (31) LNSR (24) ⌘ Pro Terminal →

Nyxoah SA (NYXH) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.87 -1.85% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.87

Nyxoah SA (NYXH) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D • SELL / AVOID Cap $88.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NYXH Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NYXH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Nyxoah SA (NASDAQ: NYXH) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $0.87 (-1.85% 1D, market cap $88.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, NYXH ranks #416 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NYXH compare to LUCD and MBOT in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), NYXH carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, LUCD (Lucid Diagnostics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $87.9M) and MBOT (Microbot Medical Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -15.8%, cap $75.2M). Among the 5-stock peer group, NYXH leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NYXH?
▼

For Nyxoah SA (NYXH), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #416 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.87 (-0.52%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510045
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (12)Whales (3)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.7% Base Target
$6 Bull$1 Base$1 Bear
📬 FREE NYXH RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NYXH)Realized 20D OHLCV Swing Band: ±10.7%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY NYXH SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (27% of score)

SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($2.5M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
53
Grade C-$1.31-27.5% Next Q
Q2 (-2Q)
50
Grade C-$0.95-9.5% Next Q
Q3 (-1Q)
48
Grade D$0.86+1.2% Next Q
Current
45
Grade D$0.87-6.3% Hist 90D α
Trajectory: C- (53) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NYXH Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NYXH currently carries a cautious 45/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.33) and Max Pain ($0.91) forces dealer call-delta covering toward $6.22.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NYXH• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NYXH Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 45%NO 55%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months

How NYXH Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$2.5M (0.1% FCF Margin)
Revenue$4.00BGross Profit $2.08B (52%)Cost of Sales $1.92BOp Profit $1.08B (27%)OpEx (R&D/SG&A) $998.4MNet Profit$865.3M (21.6%)Tax/Other $216.3M
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NYXH)

  • ✓Walkthrough of NYXH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NYXH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -69.79%🛡️ HOLDING TREND SUPPORT
2026-11-02O $0.90H $0.90L $0.87C $0.87VOL 178.8K
RES: $1.23SUP: $0.69SMA50: $1.33SMA200: $2.48
$5.21$4.01$2.82$1.62$0.43RES $1.23SUP $0.69$0.872026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NYXH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NYXH Butterfly Map → + Track NYXH →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NYXH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NYXH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NYXH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NYXH)

Health Care Rank #416 of 1016 ⚔️ LUCD vs NYXH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NYXH vs. LUCD, MBOT, QTEX, LNSR)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Nyxoah SA (NYXH) ranks #416 by composite RQD confidence (45/100, grade D) and #677 by equity capitalization ($88.9M). Within this direct 5-issuer industry benchmark cohort, NYXH leads on earnings valuation at N/A trailing P/E, while MBOT leads on capital efficiency and profitability with -15.8% ROIC and — gross margin. LUCD currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with NYXH at 45/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NYXH ACTIVE
Nyxoah SA
D 45/100 — — — -1.85% $88.9M Benchmark Subject
LUCD
Lucid Diagnostics Inc.
D 47/100 — — -35.0% -6.36% $87.9M /lucd-vs-nyxh →
MBOT
Microbot Medical Inc.
D- 41/100 — — -15.8% -2.68% $75.2M /mbot-vs-nyxh →
QTEX
QTREX Quantum Ltd.
E 31/100 — 0.7% -35.0% -7.58% $73.9M /qtex-vs-nyxh →
LNSR
LENSAR Inc.
E 24/100 — 39.4% -35.0% -2.18% $73.3M /lnsr-vs-nyxh →

2. NYXH Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Nyxoah SA (NYXH) operates in Medical/Dental Instruments (Health Care) with an equity capitalization of $88.9M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. NYXH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NYXH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Nyxoah SA (NASDAQ: NYXH) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $0.87 (-1.85% 1D, market cap $88.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, NYXH ranks #416 in composite RQD confidence.

How does NYXH compare to LUCD and MBOT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), NYXH carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, LUCD (Lucid Diagnostics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $87.9M) and MBOT (Microbot Medical Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -15.8%, cap $75.2M). Among the 5-stock peer group, NYXH leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NYXH?

For Nyxoah SA (NYXH), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #416 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NYXH trading relative to its 50-day, 200-day, and 52-week technical levels?

NYXH last traded at $0.87 (-1.85% on volume of 157,842 shares), positioning the stock -34.59% below its 50-day simple moving average ($1.33) and -64.92% below its 200-day simple moving average ($2.48). Across its 52-week range of $0.80 to $5.92, NYXH sits at the 1.4% percentile with a 14-day RSI of 31.2 (OVERSOLD (<32)) and an implied next-earnings move of ±10.7% ($1.00 to $0.96).

NYXH Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Nyxoah SA (NYXH)?

In Trailing 12 Months, NYXH converted $4.0B of revenue into a 52% gross margin, 27% operating margin, and $2.5M in free cash flow (0.1% FCF margin).

Direct Sub-Reports: NYXH RQD Cockpit NYXH 12M Forecast NYXH Earnings & Move NYXH Dividends & DRIP NYXH Insiders & 13F NYXH Whale Options NYXH Profit Sankey NYXH News & Why
ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

NYXH — Nyxoah SA: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:18:32Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, Nyxoah SA scores 45 out of 100, grade D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

  • Fundamental Cash Engine: 12 / 20 (ROIC 0%; FCF yield 0%). The cash-generation pillar is weak; the source reports no return on invested capital and no free-cash-flow yield, meaning the business is not currently producing measurable returns on capital per the source data.
  • Whale 13F Flow: 3 / 20 (institutional accumulation and options positioning). This is the lowest pillar and signals weak institutional support in the source data.
  • Insider Conviction: 9 / 20 (SEC Form 4 and Congressional PTR cluster flow). Insider signal is subdued relative to the scale of the pillar.
  • Macro Regime Fit: 8 / 20 (beta 1.0; sector sensitivity). A beta of 1.0 means the stock is reported to move in line with the market; the low pillar score reflects weak alignment with the current regime per the rating.
  • Forensic Balance Sheet: 13 / 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). This is the strongest pillar, indicating a comparatively stable balance sheet relative to the other four.

For a prospective investor evaluating the stock today, the upside case rests mainly on balance-sheet resilience and a very low share price. The valuation tradeoff is that the source data shows no positive earnings, margin, or cash-flow metrics to anchor value, so price action is not supported by reported profitability. Three of five pillars sit in the lower half of their range, which points to a rating framework that does not currently favor accumulation.

Recent Catalysts & News Wire Analysis

  • Bottom-fisher coverage (Yahoo Finance, YELLOW, MARKET WIRE): headline frames the stock as a possible bottom-fishing candidate.
  • Label expansion thesis (Seeking Alpha, YELLOW, MARKET WIRE): headline cites label expansion and a possible monopoly position in a billion-dollar market; this is an analyst thesis, not a confirmed fact.
  • Revenue outlook adjustment (Stock Titan, GREEN, CATALYST): headline states that U.S. growth is expected to improve in Q4 as the company adjusts its annual revenue outlook. This is the only item tagged as a catalyst.
  • Q3 2026 results date (MarketScreener, YELLOW, MARKET WIRE): the company is scheduled to release third-quarter 2026 financial results on November 5, 2026.
  • Seasonal returns and forecast pages (Yahoo Finance Canada, Simply Wall St, YELLOW, MARKET WIRE): reference material with no quantitative content in the source.

Risk watch: the upcoming Q3 2026 release is the nearest scheduled event. Proprietary signals from the Butterfly Supply-Chain Graph: none reported.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply-chain classification is "NONE," with no butterfly links and no proprietary signals. Upstream and downstream dependencies are therefore not available in source data. Sector affiliation is Health Care / Medical/Dental Instruments. Second-order bottlenecks cannot be identified from the source. Investors should watch the Q3 2026 results release on November 5, 2026, for any disclosure of supplier, customer, or revenue-concentration information, which the source does not provide.

Open Questions

  • What are the reported revenue, operating income, net income, and free cash flow for recent periods, given that the financials section is empty?
  • What specific revenue outlook adjustment was announced, and what magnitude of change does it imply for U.S. growth?
  • What is the company's cash and debt position in absolute terms, rather than the Debt/Equity ratio alone?
  • What institutional (13F) and insider (Form 4) transactions have occurred, given that holder data is empty?
  • What supply-chain dependencies exist, since the Butterfly graph reports none?

NYXH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Nyxoah SA (NYXH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NYXH Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NYXH Bull vs. Bear Conversation Board — What's Your Call at $0.87?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NYXH 🐻 67% BEARISH CONVICTION
1. Pick Your Side on NYXH:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.78 (-12.4%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is NYXH (D • RQD 45/100) a Buy at $0.89?

Welcome to the NYXH (Nyxoah SA) Roar Pit. Current RQD Composite is 45/100 (Roarable Sell — Underperform / Distribution Warning) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.74 (-16.9%)
Spot @ $0.89

Pump the brakes on NYXH — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on NYXH, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Nyxoah SA expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.02 (+14.6%)
Spot @ $0.89

NYXH cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on NYXH, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $0.89 (52-wk range $0.80 - $5.92), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%